Abstract: The disclosure provides FOXO1 inhibitors having beneficial properties such as selectivity and metabolic stability. FOXO1 inhibitors are useful in the treatment of diabetes.

Abstract: The present application relates to compounds of formula (I?) or formula (I), such as formula (Ia), and their pharmaceutical compositions/preparations. This application further relates to methods of treating or preventing neurodegenerative disorders, such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington disease (HD) and other CAG-triplet repeat (or polyglutamine) diseases, amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease), diffuse Lewy body disease, chorea-acanthocytosis, primary lateral sclerosis, multiple sclerosis (MS), frontotemporal dementia, Friedreich's ataxia, acute head injury, and epilepsy (repression of microglia activation).

Abstract: The present application relates to compounds of formula (I?) or formula (I), such as formula (Ia), and their pharmaceutical compositions/preparations. This application further relates to methods of treating or preventing neurodegenerative disorders, such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington disease (HD) and other CAG-triplet repeat (or polyglutamine) diseases, amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease), diffuse Lewy body disease, chorea-acanthocytosis, primary lateral sclerosis, multiple sclerosis (MS), frontotemporal dementia, Friedreich's ataxia, acute head injury, and epilepsy (repression of microglia activation).

Abstract: The present application relates to compounds of formula (I) or formula (I), such as formula (Ia), and their pharmaceutical compositions/preparations. This application further relates to methods of treating or preventing neurodegenerative disorders, such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington disease (HD) and other CAG-triplet repeat (or polyglutamine) diseases, amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease), diffuse Lewy body disease, chorea-acanthocytosis, primary lateral sclerosis, multiple sclerosis (MS), frontotemporal dementia, Friedreich's ataxia, acute head injury, and epilepsy (repression of microglia activation).

Abstract: Embodiments of the invention include an n-type region, a p-type region, and a light emitting layer disposed between the n-type region and the p-type region. The light emitting layer is a III-V material comprising nitrogen and phosphorus. The device also includes a graded region disposed between the light emitting layer and one of the p-type region and the n-type region. The composition of materials in the graded region is graded.

Abstract: Embodiments of the invention include an n-type region, a p-type region, and a light emitting layer disposed between the n-type region and the p-type region. The light emitting layer is a III-V material comprising nitrogen and phosphorus. The device also includes a graded region disposed between the light emitting layer and one of the p-type region and the n-type region. The composition of materials in the graded region is graded.

Abstract: Embodiments of the invention include an n-type region, a p-type region, and a light emitting layer disposed between the n-type region and the p-type region. The light emitting layer is a III-V material comprising nitrogen and phosphorus. The device also includes a graded region disposed between the light emitting layer and one of the p-type region and the n-type region. The composition of materials in the graded region is graded.

Abstract: The shape of a light emitting element 400;500) is designed to increase the amount of light that is able to escape from the surfaces of the light emitting element (400;500). The indices of refraction of the light emitting element (400;500) and the surrounding environment define an escape zone through which light may escape through a surface of the light emitting element (400;500). Light traveling outside the escape zone is totally internally reflected (TIR) at the surface. By increasing the number of surfaces on the light emitting element (400;500), the number of escape zones (410a-f,411a-f, 510a-h,511a-h) may be increased, with a corresponding increase in the likelihood of light escaping the surfaces. A light emitting element (400;500) comprising a polygonal surface area with more than four sides (402a-f;502a-h) exhibits a higher light extraction efficiency, and also allows a more uniform current injection, and experiences reduced mechanical stress, compared to one comprising a rectangular surface area.

Abstract: Embodiments of the invention include an n-type region, a p-type region, and a light emitting layer disposed between the n-type region and the p-type region. The light emitting layer is a III-V material comprising nitrogen and phosphorus. The device also includes a graded region disposed between the light emitting layer and one of the p-type region and the n-type region. The composition of materials in the graded region is graded.

Abstract: An integrated combat resource management device is in the form of a smartphone with a display screen and user input device. The smartphone has a set of integrated applications stored therein which when executed provide an interactive display offering dynamic real-time situational awareness information to the user. Configuration files contain user-specific profiles. A launcher application offers access control and the management of several user profiles on the same smartphone such that upon successful login the appropriate user-specific profile is applied.

Abstract: The present application describes general process for the preparation of amino-substituted gamma-lactams involving the reaction of synthons of the general Formulae (I) and (VI): with amines. The processes are amenable to solid phase synthetic techniques and therefore allow the efficient incorporation of amino-substituted gamma-lactams into a wide variety of structural scaffolds, including, in particular peptides.